The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial

Cephalalgia ◽  
2019 ◽  
Vol 39 (5) ◽  
pp. 648-654 ◽  
Author(s):  
Parisa Hajihashemi ◽  
Gholamreza Askari ◽  
Fariborz Khorvash ◽  
Mohammad Reza Maracy ◽  
Mojgan Nourian
Keyword(s):  
Coenzyme Q10 ◽  
Metabolic Disorders ◽  
Primary Outcome ◽  
Serum Levels ◽  
Parallel Study ◽  
Double Blind ◽  
Beneficial Effects ◽  
Headache Diary ◽  
Combined Supplementation ◽  
To Receive

Purpose The present study aimed to determine the effects of combined supplementation of Coenzyme Q10 with L-carnitine on mitochondrial metabolic disorders marker and migraine symptoms among migraine patients. Methods A total of 56 men and women, between 20–40 years of age with migraine headache, participated in this randomized, double-blind, placebo-controlled, parallel study. The subjects were randomly assigned to receive either 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine at the same time and/or placebo tablets for 8 weeks. The measurements were completed at the beginning and end of the study. The primary outcome was severity of headache attacks. The secondary outcomes included duration, frequency of headache attacks, the headache diary results (HDR), and serum levels of lactate. Results A significant reduction was obtained in serum levels of lactate (−2.28 mg/dl, 95% CI: −3.65, −0.90; p = 0.002), severity (−3.03, 95% CI: −3.65, −2.40; p ≤ 0.001), duration (−7.67, 95% CI: −11.47, −3.90; p ≤ 0.001), frequency (−5.42, 95% CI: −7.31, −3.53; p ≤ 0.001) and HDR (−103.03, 95% CI: −145.76, −60.29; p ≤ 0.001) after 8 weeks. Conclusion This double-blind parallel study provides evidences supporting the beneficial effects of Coenzyme Q10 and L-carnitine supplements on serum levels of lactate and migraine symptoms. Trial registration IRCT20121216011763N21.

Comparison of the effectiveness of circumferential versus non-circumferential spread in median and ulnar nerve blocks. A double-blind randomized clinical trial

2020 ◽  
Vol 45 (5) ◽  
pp. 362-366
Author(s):  
Paula Dieguez-Garcia ◽  
Servando Lopez-Alvarez ◽  
Jorge Juncal ◽  
Ana M Lopez ◽  
Xavier Sala-Blanch
Keyword(s):  
Median Nerve ◽  
Ulnar Nerve ◽  
Motor Block ◽  
Primary Outcome ◽  
Sensory Block ◽  
Nerve Blocks ◽  
Double Blind ◽  
Registration Number ◽  
Tunnel Syndrome ◽  
To Receive

Background and objectivesCircumferential (C) spread of local anesthetic around the nerve is recommended for a successful nerve block. We tested the hypothesis that C spread produces a more complete block than non-circumferential (NC) spread.MethodsWe randomized 124 patients undergoing open carpal tunnel syndrome surgery to receive C or NC spread ultrasound-guided median and ulnar nerve blocks. The primary outcome was the proportion of patients who developed complete sensory block measured at 5, 15 and 30 min. The loss of cold sensation was graded as: 0 (complete block), 1 (incomplete block), or 2 (no block). Secondary outcomes included motor block, nerve swelling and adverse events.ResultsIn group C, complete sensory block at 5 min was 2.4 (95% CI 1.0 to 5.7; p=0.04) times more frequent in the median nerve and 3.0 (95% CI 1.2 to 7.2; p=0.01) times more frequent in the ulnar nerve compared with group C. However, at 15 and 30 min, it was similar between groups. Complete motor block was more frequent in group C than in group NC for both the median nerve: 1.5 (95% CI 1.1 to 2.2; p<0.01) at 15 min, 1.1 (95% CI 1.0 to 1.2; p=0.02) at 30 min, and the ulnar nerve: 1.7 (95% CI 1.2 to 2.6; p<0.01) at 15 min, 1.2 (95% CI 1.0 to 1.4; p<0.01) at 30 min. The incidence of nerve swelling and adverse effects was similar between groups.ConclusionsC spread around the median and ulnar nerves at the level of the antecubital fossa generates more complete sensory and motor blocks compared with NC spread.Trial registration numberEudraCT 2011-002608-34 and NCT01603680

Evaluation of the effects of roselle (Hibiscus sabdariffa L.) on oxidative stress and serum levels of lipids, insulin and hs-CRP in adult patients with metabolic syndrome: a double-blind placebo-controlled clinical trial

2016 ◽  
Vol 13 (2) ◽  
Author(s):  
Sedigheh Asgary ◽  
Rasool Soltani ◽  
Mohsen Zolghadr ◽  
Mahtab Keshvari ◽  
Nizal Sarrafzadegan
Keyword(s):  
Oxidative Stress ◽  
Serum Levels ◽  
Adult Patients ◽  
Controlled Clinical Trial ◽  
Hibiscus Sabdariffa ◽  
Daily Consumption ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Hs Crp ◽  
To Receive

Abstract: Roselle (: Forty adult patients with MetS were randomly assigned to receive either 500 mg of:: Daily consumption of 500 mg of

A Comparison of Loratadine, a New Nonsedating Antihistamine, with Clemastine and Placebo in Patients with Fall Seasonal Allergic Rhinitis

1987 ◽  
Vol 1 (3) ◽  
pp. 151-154 ◽  
Author(s):  
James P. Kemp ◽  
Sami L. Bahna ◽  
Paul Chervinsky ◽  
Gary S. Rachelefsky ◽  
James M. Seltzer ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Parallel Study ◽  
Double Blind ◽  
Daily Diaries ◽  
Ocular Symptoms ◽  
Symptom Scores ◽  
The Mean ◽  
Long Acting ◽  
To Receive

Loratadine is a new nonsedating long-acting H1-antagonist which has been shown to be effective at various doses in controlling symptoms of spring seasonal allergic rhinitis. In this multicenter, double-blind, parallel study, 313 adolescent and adult patients with moderate to severe, skin-test positive, fall seasonal rhinitis were randomized to receive either loratadine, 10 mg, in the morning and placebo in the evening, clemastine 1 mg. b.i.d., or placebo b.i.d. for 2 weeks. Patients maintained daily diaries of nasal and ocular symptoms and of adverse effects. They were evaluated before and 7 and 14 days after starting treatment. The mean symptom scores on days 7 and 14 showed greater improvement with both loratadine and clemastine treatments than with placebo. The incidence of somnolence in the loratadine group by comparison with the placebo group was not statistically different, whereas clemastine caused significantly more drowsiness than did placebo. We conclude that loratadine, 10 mg, once a day is as effective as clemastine b.i.d. in decreasing the symptoms of fall seasonal rhinitis and the incidence of somnolence with loratadine is not statistically different from that with placebo.

scholarly journals Effect of zinc supplementation on symptoms among patients with migraine

2019 ◽  
Keyword(s):  
Zinc Supplementation ◽  
Headache Frequency ◽  
Effective Treatment Option ◽  
Double Blind ◽  
Headache Severity ◽  
Significant Difference ◽  
Headache Diary ◽  
Islamic Republic Of Iran ◽  
To Receive ◽  
Controlled Clinical Study

Background& aims: Prevalence of migraine is estimated at 14.7% and 14% around the world and Iran, respectively. Zinc deficiency has become one of the nutritional problems worldwide. People with migraines have lower levels of zinc, also, we are informed, that there have been no studies about the effect of zinc on symptoms among migraine patients. The aim of our study was to determine the effect of zinc supplementation on symptoms and CRP among patients with migraine. Materials and Method: This double-blind, randomized placebo-controlled, clinical study was conducted on 80 patients with migraine in Isfahan, Islamic Republic of Iran at 2016. Participants were randomly assigned to receive zinc sulphate supplementation including (220 mg/day as 50 mg of elemental zinc, Alhavi Company) or matching placebo (starch). Symptoms of migraine attacks including Severity of headache, headache frequency, duration, headache diary result (HDR) and CRP levels were determined for each patient at baseline and at the end of the trial. Results: In the baseline symptoms of migraine there was no significant difference between the two groups. In addition, the intervention compared to placebo resulted in a significant decrease in headache severity (P=0.048), headache frequency (P=0.026) and HDR (P=0.02), but, mean difference for duration of migraine attacks was borderline statistically significant trend (P=0.092). Conclusion: This study showed that zinc supplementation for 8 weeks may be an effective treatment option on symptoms of migraine

scholarly journals Possible beneficial effects of amlodipine, lisinopril, and their Combination on lipid profile in hypertensive patients

2009 ◽  
Vol 33 (2) ◽  
pp. 126-137
Author(s):  
Fadia Y. Alhamdani
Keyword(s):  
Blood Pressure ◽  
Angiotensin Converting Enzyme ◽  
Lipid Profile ◽  
Poor Response ◽  
Serum Levels ◽  
Combination Group ◽  
Converting Enzyme ◽  
Double Blind ◽  
Beneficial Effects ◽  
Long Acting

It is well known that monotherapy does not provide therapeutic response in all hypertensive. Somepatients show an excellent response, while in others there is a poor response. Combinationantihypertensive therapy is administered when blood pressure is inadequately controlled bymonotherapy to achieve a balanced and additive antihypertensive effect with minimum adverse effects.Both angiotensin converting enzyme (ACE) inhibitors and dihydropyridine type of calcium antagonistsare well established and widely used in monotherapy. An understanding of differences in themechanism of action of these agents allows a logical approach for the use of these agents as acombination therapy. This study was designed to evaluate the possible beneficial effects of long actingcalcium channel blocker, amlodipine and the long acting Angiotensin converting enzyme (ACE)inhibitor, lisinopril given either alone or in combination in patients with essential hypertension on lipidprofile (LDL-C and HDL-C) and on other parameters using a randomized double blind, crossoverstudy. The study includes 150 patients with systolic blood pressure (SBP)>140 mmHg and diastolicblood pressure (DBP) >90 mmHg received amlodipine 5 mg, lisinopril 5 mg and their combinationprior randomization schedule. Systolic, diastolic blood pressure and pulse rate were recorded at weeklyintervals while, serum levels of urea, creatinine, LDL-C and HDL-C where recorded at monthlyintervals, the duration of this study was 3 months. Results were obtained using paired students t-test,differences were considered significant with (p<0.05).A significant decline in SBP and DBP in all treatment groups (p<0.05) was recorded, the reductiontend to be more pronounced in the combination group. Moreover, there was a significant effect ofcombination on the heart rate, serum level of urea and creatinine, beside that, the level of HDL wassignificantly elevated with amlodipine and combination. We concluded that combination had additionalblood pressure lowering effect when compared either with amlodipine or lisinopril alone, in addition tothe greater effect on lipid profile which demonstrated that this combination is potentialantiatherosclerotic agent.

Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial.

1986 ◽  
Vol 4 (1) ◽  
pp. 98-103 ◽  
Author(s):  
L B Anthony ◽  
M G Krozely ◽  
N J Woodward ◽  
J D Hainsworth ◽  
K R Hande ◽  
...  
Keyword(s):  
High Performance ◽  
Serum Levels ◽  
Autonomic Arousal ◽  
High Dose ◽  
Tumor Type ◽  
Double Blind ◽  
Antiemetic Effect ◽  
Dose Oral ◽  
The Mean ◽  
To Receive

In a study of the antiemetic effectiveness of high-dose oral metoclopramide, 66 previously untreated patients receiving 60 mg/m2 cisplatin were entered into a double-blind randomized trial. Patients were stratified according to age and tumor type, then randomized to receive either oral or intravenous (IV) high-dose metoclopramide. Patients were evaluated for antiemetic protection, toxicity, affect (anxiety, hostility, and depression), and autonomic arousal (pulse rate and blood pressure) at three-hour intervals on the day of their chemotherapy. Metoclopramide serum levels were measured by high-performance liquid chromatography. Results indicated no significant differences between the oral and IV groups on any measurement of antiemetic protection, affect, or autonomic arousal. There were also no significant differences in side effects except for frequency of stools; patients who received oral metoclopramide had significantly more stools than patients who received IV metoclopramide. The mean (+/- SD) serum metoclopramide level at four hours achieved orally was 1,171 +/- 660 ng/mL; the mean (+/- SD) level achieved IV was 1,030 +/- 392 ng/mL (P = .498). We conclude that high-dose oral and IV regimens of metoclopramide as administered in this study have equivalent antiemetic efficacy in previously untreated patients receiving 60 mg/m2 cisplatin.

Efficacy of Omega-3 and Korean Red Ginseng in Children with Subthreshold ADHD: A Double-Blind, Randomized, Placebo-Controlled Trial

2020 ◽  
pp. 108705472095186
Author(s):  
Jeewon Lee ◽  
Soyoung Irene Lee
Keyword(s):  
Primary Outcome ◽  
Rating Scale ◽  
Controlled Trial ◽  
Adhd Symptoms ◽  
Omega 3 ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Double Blind ◽  
Beneficial Effects ◽  
Clinical Awareness

Objective: The purpose of the present study was to investigate the efficacy of combined omega-3 and Korean red ginseng supplementation on ADHD symptoms and cognitive function in children with subthreshold ADHD. Method: 120 children from 6 to 12 years with subthreshold ADHD were enrolled in this 12-week, double-blind, randomized, placebocontrolled study. The primary outcome was measured by Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Children Behavior Check List (CBCL), and neuropsychological tests assessing attention, memory, and executive function were included as secondary primary outcome measures. Results: Significant effects on the scores of ADHDRS, as well as several subscales of CBCL including ADHD and attention problem subscales were revealed. Conclusion: The combination of omega-3 and Korean red ginseng may have beneficial effects in children with subthreshold ADHD. Increased clinical awareness of ADHD symptoms even at a subthreshold level is needed.

scholarly journals The application of Reiki in nurses diagnosed with Burnout Syndrome has beneficial effects on concentration of salivary IgA and blood pressure

2011 ◽  
Vol 19 (5) ◽  
pp. 1132-1138 ◽  
Author(s):  
Lourdes Díaz-Rodríguez ◽  
Manuel Arroyo-Morales ◽  
Irene Cantarero-Villanueva ◽  
Carolina Férnandez-Lao ◽  
Marie Polley ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Immunoglobulin A ◽  
Burnout Syndrome ◽  
Double Blind ◽  
Beneficial Effects ◽  
Control Intervention ◽  
Hand Off ◽  
Sham Intervention ◽  
To Receive

This study aimed to investigate the immediate effects of the secretory immunoglobulin A (sIgA), α-amylase activity and blood pressure levels after the application of a Reiki session in nurses with Burnout Syndrome. A randomized, double-blind, placebo-controlled, crossover design was conducted to compare the immediate effects of Reiki versus control intervention (Hand-off sham intervention) in nurses with Burnout Syndrome. Sample was composed of eighteen nurses (aged 34-56 years) with burnout syndrome. Participants were randomly assigned to receive either a Reiki treatment or a placebo (sham Reiki) treatment, according to the established order in two different days. The ANOVA showed a significant interaction time x intervention for diastolic blood pressure (F=4.92, P=0.04) and sIgA concentration (F=4.71, P=0.04). A Reiki session can produce an immediate and statistically significant improvement in sIgA concentration and diastolic blood pressure in nurses with Burnout Syndrome.

Alpha-Ketoglutarate Decreases Serum Levels of C-terminal Cross-Linking Telopeptide of Type I Collagen (CTX) in Postmenopausal Women with Osteopenia: Six-Month Study

2007 ◽  
Vol 77 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Filip ◽  
Pierzynowski ◽  
Lindegard ◽  
Wernerman ◽  
Haratym-Maj ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Skeletal Development ◽  
Serum Levels ◽  
Study Groups ◽  
Type I ◽  
Mineral Density ◽  
Double Blind ◽  
Beneficial Effects

Several studies have shown that α-ketoglutaric acid (AKG) increases serum levels of proline and has beneficial effects on skeletal development. We studied the effect of α-ketoglutaric (AKG) acid calcium salt (6 g AKG and 1.68 Ca/day) or calcium alone (1.68 Ca/day) on serum C-terminal cross-linked telopeptide of type I collagen (CTX) and osteocalcin (OC), as well as on lumbar spine bone mineral density (BMD) in a randomized, parallel group, double-blind, 6-month study conducted on 76 postmenopausal women with osteopenia. The maximum decrease of the mean CTX level in the AKG-Ca group was observed after 24 weeks (37.0%, p = 0.006). The differences in CTX between study groups were statistically significant after 12 and 24 weeks. The OC serum level was not affected by treatments. The BMD of the AKG-Ca group increased by 1.6% from baseline; however, the difference between treatment groups was estimated as 0.9% (non-significant). This study suggests the potential usefulness of AKG-Ca in osteopenic postmenopausal women. AKG-Ca induced beneficial changes in serum CTX, which was consistent with preserving the bone mass in the lumbar spine; however, the long-term effect needs to be further investigated.

Sign in / Sign up

Export Citation Format

Share Document